Norgine

Executive Summary

Norgine is a leading European specialist pharmaceutical company with a heritage dating back to 1906. Headquartered in Amsterdam and with a strong operational presence in Vienna, Austria, the company is dedicated to acquiring, developing, and commercializing innovative medicines, primarily in the fields of gastroenterology and hepatology. Through its focused portfolio and global partnership network, Norgine serves approximately 25 million patients annually, underscoring its significant impact on healthcare across Europe. The company’s agile infrastructure and strategic collaborations enable it to efficiently bring new therapies to market, addressing unmet medical needs in gastrointestinal and liver diseases. As a private entity with a long-standing reputation, Norgine continues to leverage its expertise in specialty pharmaceuticals to drive growth. While the company maintains a robust commercial product portfolio, its pipeline for near-term catalysts is not currently publicly detailed. However, Norgine’s consistent patient reach and established market position suggest a steady operational trajectory. Future developments may include expansion of existing product lines, new partnership agreements, or regulatory approvals in its core therapeutic areas, though no specific catalysts have been identified at this time.